Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01308346
Other study ID # 10-390
Secondary ID
Status Terminated
Phase N/A
First received March 2, 2011
Last updated May 6, 2013
Start date November 2011
Est. completion date April 2013

Study information

Verified date May 2013
Source Abbott Vascular
Contact n/a
Is FDA regulated No
Health authority Australia: Department of Health and Ageing Therapeutic Goods Administration
Study type Interventional

Clinical Trial Summary

The target enrollment goal for the trial was to enroll 36 subjects. However due to a challenging protocol inclusion/ exclusion criteria, only one subject was enrolled since the trial was initiated in June 2011.

To evaluate the following in participants undergoing coronary artery scaffolding/stenting for significant coronary artery disease:

- The acute (post-implantation) effect of an implanted bioresorbable vascular scaffold (BVS) or metallic drug eluting stent (mDES) on coronary blood flow and physiological responsiveness of the target coronary artery

- The long-term (2 years) effect of an implanted BVS or mDES on coronary blood flow and physiological responsiveness of the target coronary artery


Description:

- Prospective, randomized, single-blinded, multi-center clinical investigation comparing target vessel and non-intervened, self-control vessel within participants and between participants undergoing BVS or mDES deployment for the treatment of a single de novo native coronary artery lesion

- The investigation will include two arms:

- Study device (BVS) arm: Abbott Vascular's Everolimus-Eluting Bioresorbable Vascular Scaffold

- Control device (mDES) arm: Abbott Vascular's Everolimus-Eluting XIENCE V or XIENCE PRIME


Recruitment information / eligibility

Status Terminated
Enrollment 1
Est. completion date April 2013
Est. primary completion date April 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Participant must be a male of at least 18 years of age or a female that is post-menopausal and not on hormone replacement therapy.

2. Participant is able to verbally confirm understanding of risks, benefits and treatment alternatives and he/she or his/her legally authorized representative must provide written informed consent prior to any clinical investigation related procedure, as approved by the appropriate Ethics Committee of the respective clinical site.

3. Participant must have evidence of myocardial ischemia (e.g., stable or unstable angina, silent ischemia with a positive functional study).

4. Participant must be an acceptable candidate for coronary artery bypass graft (CABG) surgery.

5. Participant must agree to undergo all clinical investigation plan-required follow-up visits.

6. Participant must agree not to participate in any other clinical investigation for a period of 2 years following the index procedure. This includes clinical trials of medications and invasive procedures. Only questionnaire-based studies are allowed.

Angiographic Inclusion Criteria:

1. A single de novo native coronary artery lesion suitable to be treated by either a BVS or a mDES.

2. Target lesion must be located in a native coronary artery in which the mean proximal and distal vessel diameter of the target lesion (Dmean) fall within the range of = 2.25 mm and = 3.25 mm and the target lesion length measures = 22 mm as assessed by IVUS.

3. Target lesion must be located in the main branch of a major epicardial vessel (i.e., LAD, LCX, or RCA) with a visually estimated diameter stenosis of = 50% and < 100% with a TIMI flow of = 1.

4. Participant must have an additional angiographically smooth (< 40% diameter stenosis) non-target vessel to act as an intra-participant control vessel (self-control vessel). The self-control vessel must be the main branch of a major epicardial vessel (i.e., LAD, LCX, or RCA).

5. Coronary anatomy must be suitable for IVUS, OCT, and pressure and flow wire instrumentation.

General Exclusion Criteria:

1. Participant has a known diagnosis of spontaneous acute myocardial infarction (AMI) within 14 days preceding the index procedure.

2. Participant has high-risk acute coronary syndrome (e.g., dynamic ST-T wave change on ECG or recurrent chest pain/nitrate-unresponsive prolonged chest pain at rest within 48 hours prior to the index procedure).

3. Participant has any evidence of myocardial infarct in the territory subtended by the proposed target vessel or self-control vessel.

4. Participant has current unstable arrhythmias.

5. Participant has chronic atrial fibrillation.

6. Participant has a known left ventricular ejection fraction (LVEF) < 40%.

7. Participant has received a heart transplant or any other organ transplant or is on a waiting list for any organ transplant.

8. Participant has previously had CABG or mitral or aortic valve repair/replacement.

9. Participant is receiving or scheduled to receive chemotherapy for malignancy within 30 days prior to or after the index procedure.

10. Participant is receiving immunosuppressant therapy or has known immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematosus, etc.).

11. Participant has a chronic systemic condition or medication likely to interfere with coronary physiology and/or conduit artery function (e.g., chronic inflammatory condition, chronic renal failure, or chronic obstructive pulmonary disease).

12. Participant has known renal insufficiency.

13. Participant is receiving or scheduled to receive any planned radiotherapy.

14. Participant is receiving chronic anticoagulation therapy (e.g., heparin, coumadin) at the onset of the clinical investigation.

15. Participant has a known hypersensitivity or contraindication to aspirin, heparin/bivalirudin, anti-platelet medications specified for use in the study (clopidogrel, prasugrel and ticlopidine, inclusive), everolimus, poly (L-lactide), poly (DL-lactide), cobalt, chromium, nickel, platinum, tungsten, acrylic and fluoro polymers, or contrast sensitivity that cannot be adequately pre-medicated.

16. Elective surgery is planned within the first 6 months after the index procedure that will require discontinuing aspirin, clopidogrel, prasugrel, or ticlopidine.

17. Participant has a platelet count < 100,000 cells/mm3 or > 700,000 cells/mm3, a WBC of < 3,000 cells/mm3, or documented or suspected liver disease (including laboratory evidence of hepatitis) within 7 days prior to the index procedure.

18. Participant has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions.

19. Participant has had a cerebrovascular accident/stroke (CVA) or transient ischemic neurological attack (TIA) within the past 6 months.

20. Participant has had a significant gastro-intestinal or significant urinary bleed within the past 6 months.

21. Participant has extensive peripheral vascular disease that precludes safe 6 French sheath insertion.

22. Participant has a history of paradoxical exercise-induced vasoconstriction that is consistent with myocardial bridging in the coronary anatomy.

23. Participant has other medical illness (e.g., cancer or congestive heart failure) or known history of substance abuse (alcohol, cocaine, heroin etc.) that in the judgment of the Investigator may cause non-compliance with the clinical investigation plan, confound the data interpretation or is associated with a limited life expectancy.

24. Participant is currently participating in another clinical investigation that has not yet reached its primary endpoint.

25. Percutaneous interventions for lesions in the third major epicardial vessel (the one that does not contain the target or the self-control vessel) were performed within 30 days preceding the index procedure or are planned to be done within 6 months following the index procedure.

26. Planned PCI procedures in the target vessel (and/or any of its side branches) or the self-control vessel (and/or any of its side branches) within 2 years following the index procedure.

27. Participant who does not suspend drugs that will influence vaso-function.

Angiographic Exclusion Criteria

1. Target lesion meets any of the following criteria:

1. Left main location;

2. RCA aorto-ostial location (within 10 mm from expected proximal stent/scaffold edge);

3. LAD or LCX ostial location (within 10 mm from expected proximal stent/scaffold edge);

4. Involves a bifurcation with a side branch = 2 mm in diameter, an ostial lesion > 40% stenosed by visual estimation, or a side branch requiring pre-dilatation;

5. Total occlusion (TIMI flow 0) prior to wire crossing;

6. Excessive tortuosity proximal to or within the lesion;

7. Extreme angulation (= 90°) proximal to or within the lesion;

8. Heavy calcification in the lesion;

9. Located in a side branch.

2. Participant has a high probability that a procedure other than pre-dilatation, scaffold/stent implantation, and post-dilatation (if applicable) will be required at the time of index procedure for treatment of the target vessel (e.g., atherectomy, cutting balloon or brachytherapy).

3. The target vessel (and/or any of its side branches) or the self-control vessel (and/or any of its side branches) contains visible thrombus.

4. The target vessel or the self-control vessel has previously been treated by any PCI procedures.

5. A side branch of the target vessel or a side branch of the self-control vessel has received any percutaneous interventions within 30 days prior to the index procedure.

6. Another clinically significant lesion is located in the target vessel (and/or any of its side branches) or the self-control vessel (and/or any of its side branches) that may require PCI treatments within 2 years following the index procedure.

7. Participant has evidence of myocardial bridging in the coronary anatomy during the angiographic evaluation.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)


Intervention

Device:
Bioabsorbable Vascular Solutions Everolimus Eluting Coronary Stent System (BVS EECSS)
Bioabsorbable Everolimus Eluting Coronary Stent
XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)

Locations

Country Name City State
Australia Royal Adelaide Hospital Adelaide
Australia Austin Health Heidelberg Victoria
Australia Monash Medical Centre Melbourne
China Queen Elizabeth Hong Kong
Netherlands Maasstad Ziekenhuis Rotterdam
Singapore National Heart Centre Singapore Singapore

Sponsors (1)

Lead Sponsor Collaborator
Abbott Vascular

Countries where clinical trial is conducted

Australia,  China,  Netherlands,  Singapore, 

Outcome

Type Measure Description Time frame Safety issue
Primary Coronary artery endothelial responsiveness Change of vessel diameter by 1) pacing, 2) hand-grip and 3) acetylcholine injection Post procedure Yes
Secondary Coronary artery cross-sectional compliance and cross-sectional distensibility Cross-sectional compliance is defined as change in area per unit change in pressure; cross-sectional distensibility is defined as compliance/diastolic cross-sectional area. Post procedure Yes
Secondary Target artery endothelial shear stress distribution Wall Shear Stress (WSS) will be determined from flow velocity and blood viscosity Post procedure Yes
Secondary Wave intensity patterns in the coronary arteries Looking at re-distribution of energy in the blood flow along the coronary artery. Post procedure Yes
Secondary Systolic and diastolic coronary artery impedance Post procedure Yes
Secondary Clinical device success Successful delivery and deployment of the Clinical Investigation scaffold at the target lesion and successful withdrawal of the scaffold delivery system. Post procedure Yes
Secondary Clinical Procedure Success Successful delivery and deployment of the Clinical Investigation scaffold at the target lesion and successful withdrawal of the scaffold delivery system without the occurrence of ischemia driven major adverse cardiac event (MACE). during the hospital stay with a maximum of 7 days post index procedure. Yes
Secondary Cardiac Death (CD) 180 days Yes
Secondary Cardiac Death (CD) 1 year Yes
Secondary Cardiac Death (CD) 2 years Yes
Secondary Myocardial Infarction (MI) 180 days Yes
Secondary Myocardial Infarction (MI) 1 year Yes
Secondary Myocardial Infarction (MI) 2 years Yes
Secondary Target Vessel Myocardial Infarction (TV-MI) 180 days Yes
Secondary Target Vessel Myocardial Infarction (TV-MI) 1 year Yes
Secondary Target Vessel Myocardial Infarction (TV-MI) 2 years Yes
Secondary All Death, All MI, All Revascularization (DMR) 180 days Yes
Secondary All Death, All MI, All Revascularization (DMR) 1 year Yes
Secondary All Death, All MI, All Revascularization (DMR) 2 years Yes
Secondary Ischemia-Driven MACE (ID-MACE) 180 days Yes
Secondary Ischemia-Driven MACE (ID-MACE) 1 year Yes
Secondary Ischemia-Driven MACE (ID-MACE) 2 years Yes
Secondary Ischemia-Driven Target Vessel Failure (ID-TVF) 180 days Yes
Secondary Ischemia-Driven Target Vessel Failure (ID-TVF) 1 year Yes
Secondary Ischemia-Driven Target Vessel Failure (ID-TVF) 2 years Yes
Secondary Ischemia-Driven Target Vessel Revascularization (ID-TVR) 180 days Yes
Secondary Ischemia-Driven Target Vessel Revascularization (ID-TVR) 1 year Yes
Secondary Ischemia-Driven Target Vessel Revascularization (ID-TVR) 2 years Yes
Secondary Ischemia-Driven Self-Control Vessel Revascularization (ID-SCVR) 180 days Yes
Secondary Ischemia-Driven Self-Control Vessel Revascularization (ID-SCVR) 1 year Yes
Secondary Ischemia-Driven Self-Control Vessel Revascularization (ID-SCVR) 2 years Yes
Secondary Ischemia-Driven Non-Target, Non-Self-Control Vessel Revascularization (ID-NTNSCVR) 180 days Yes
Secondary Ischemia-Driven Non-Target, Non-Self-Control Vessel Revascularization (ID-NTNSCVR) 1 year Yes
Secondary Ischemia-Driven Non-Target, Non-Self-Control Vessel Revascularization (ID-NTNSCVR) 2 years Yes
Secondary Ischemia-Driven Target Lesion Revascularization (ID-TLR) 180 days Yes
Secondary Ischemia-Driven Target Lesion Revascularization (ID-TLR) 1 year Yes
Secondary Ischemia-Driven Target Lesion Revascularization (ID-TLR) 2 years Yes
Secondary Scaffold/Stent thrombosis 180 days Yes
Secondary Scaffold/Stent thrombosis 1 year Yes
Secondary Scaffold/Stent thrombosis 2 years Yes
Secondary Coronary artery endothelial responsiveness Change of vessel diameter by 1) pacing, 2) hand-grip and 3) acetylcholine injection 2 years Yes
Secondary Coronary artery cross-sectional compliance and cross-sectional distensibility Cross-sectional compliance is defined as change in area per unit change in pressure; cross-sectional distensibility is defined as compliance/diastolic cross-sectional area. 2 years Yes
Secondary Target artery endothelial shear stress distribution Wall Shear Stress (WSS) will be determined from flow velocity and blood viscosity 2 years Yes
Secondary Wave intensity patterns in the coronary arteries Looking at re-distribution of energy in the blood flow along the coronary artery. 2 years Yes
Secondary Systolic and diastolic coronary artery impedance 2 years Yes
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions N/A